Cansortium Reports First Quarter 2021 Financial Results

<br /> Cansortium Reports First Quarter 2021 Financial Results<br />

PR Newswire


Q1 Revenue up 49% YoY to

$15.1 Million

; Adjusted EBITDA up Significantly to

$4.4 Million


Management to Host Conference Call Today at

4:30 P.M. Eastern Time


MIAMI, Fla.

,

May 28, 2021

/PRNewswire/ –

Cansortium Inc.

(CSE: TIUM.U) (OTCQB: CNTMF) (“Cansortium” or the “Company”), a vertically-integrated cannabis company operating under the Fluentâ„¢ brand, today announced financial results for the first quarter ended

March 31, 2021

, as well as recent operational highlights. Unless otherwise indicated, all results are presented in U.S. dollars.

“The momentum from last year has carried into 2021 as we generated another quarter of record revenue and adjusted EBITDA

1

,” said Chief Executive Officer

Robert Beasley

. “We have moved well past our turnaround phase and have returned to consistent growth and profitability. In fact, we followed up Q1 with another record month of sales in April, and we continue to expect a step function in growth in the back half of the year as new dispensaries and cultivation capacity come online.

“Our expansion initiatives in both

Florida

and

Pennsylvania

have been fully funded by our recent debt and equity financings of nearly

$90 million

. By the end of 2021, we anticipate having a total of 30 dispensaries operational along with over 150,000 ft

2

of cultivation capacity, positioning us well for an even stronger 2022.”



Q1 2021 Financial Highlights (vs. Q1 2020)

  • Revenue increased 49% to

    $15.1 million

    compared to

    $10.2 million

  • Florida

    revenue increased 41.4% to

    $13.1 million

    compared to

    $9.3 million
  • Adjusted gross profit

    2

    increased 49% to

    $9.7 million

    or 64.2% of revenue, compared to

    $6.5 million

    or 64.0% of revenue
  • Net loss totaled

    $(5.1) million

    or

    $(0.03)

    per share, compared to a net loss of

    $(13.9) million

    or

    $(0.07)

    per share
  • Adjusted EBITDA increased significantly to

    $4.4 million

    compared to

    $0.7 million


___________________________



1

Adjusted EBITDA is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Company calculates adjusted EBITDA from EBITDA plus (minus) unrealized loss (gain) on embedded derivatives, plus (minus) certain one-time non-operating expenses, as determined by management. A reconciliation from adjusted EBITDA to net loss is included in the accompanying financial schedules.



2

Adjusted gross profit is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Company calculates adjusted gross profit from gross profit plus (minus) the changes in fair value of biological assets, as presented in the consolidated statement of operations.



Recent Operational Highlights

  • Generated record April sales

    Florida

    highlighted by record volumes on the 4/20 cannabis holiday
  • Launched 21 new flower strains in

    Florida

    as well as several new products, including three new Moods flavors and

    Jane West

    pipes
  • In April, the Company completed a

    $17 million

    private placement and

    $71 million

    secured term loan, which provides the resources and working capital needed to support Cansortium’s growth and expansion
  • In May, the Company satisfied and cancelled approximately

    $43 million

    of legacy debt and redeemed

    $5 million

    of convertible notes
  • As of

    May 28, 2021

    , the Company had approximately

    $30 million

    of cash and cash equivalents,

    $71 million

    of debt and a

    $5 million

    convertible note outstanding, as well as approximately 267 million fully diluted shares outstanding (based on treasury stock method and share price on

    May 27, 2021

    )



2021 Outlook



The Company is reiterating its previously issued annual guidance of revenue between approximately

$90 million

to

$100 million

, as well as adjusted EBITDA of approximately

$30 million

to

$35 million

.

In

Florida

, Cansortium continues to expect a total of 27 dispensaries to be operational by the end of 2021 (up from its current 24 locations in FL), with an additional four identified locations by year-end. The Company also continues to expect approximately

$70

-80 million of 2021 revenue to come from its operations in

Florida

.

In

Pennsylvania

, the Company continues to expect opening an additional dispensary in Q3 2021, with a third dispensary opening in Q4 2021.

In

Michigan

, the Company has approximately 2,600 lbs. of biomass in inventory and 900 lbs. of flower prepared for sale. The Company anticipates that all will be sold in the next 30-60 days and based on current market prices, will generate approximately

$3 million

of revenue.

The Company’s unaudited consolidated financial statements and accompanying notes, along with the Management Discussion and Analysis (MD&A), are available under the Company’s profile on SEDAR at

www.sedar.com

and are also accessible through the Investor Relations section of the Company’s website at

www.getfluent.com

.



Conference Call



The Company will host a conference call and live audio webcast today at

4:30 p.m. Eastern time

to discuss its financial results and operational highlights.


Toll-free

dial-in number: 1-800-319-4610

International dial-in number: (604) 638-5340

Conference ID: 10014932

Link:

Cansortium Q1 2021 Webcast

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Elevate IR at (949) 200-4603.

The conference call will also be available for replay via the News & Events section of the Company’s investor relations website at

https://investors.getfluent.com/

.



About Cansortium Inc.



Cansortium is a vertically-integrated cannabis company with licenses and operations in

Florida

,

Pennsylvania

,

Michigan

and

Texas

. The Company operates under the Fluentâ„¢ brand and is dedicated to being one of the highest quality cannabis companies for the communities it serves. This is driven by Cansortium’s unrelenting commitment to operational excellence in cultivation, production, distribution and retail. The Company is headquartered in

Miami, Florida

.

Cansortium Inc.’s common shares trade on the CSE under the symbol “TIUM.U” and on the OTCQB Venture Market under the symbol “CNTMF.” For more information about the Company, please visit

www.getfluent.com

.



Forward-Looking Information



Certain information in this news release may constitute forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved”. In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates, and projections regarding future events.

Forward-looking information is necessarily based on many opinions, assumptions, and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in the public documents of the Company available at

www.sedar.com

. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

For further information:

www.getfluent.com



CANSORTIUM INC.



CONSOLIDATED STATEMENT OF FINANCIAL POSITION



(USD ‘000)



March 31, 2021



December 31, 2020



Assets


Current assets


Cash and cash equivalents


$


3,114


$


3,392


Accounts receivable


115


148


Inventory, net


6,860


5,006


Biological assets


5,536


1,914


Note receivable


3,887


3,859


Prepaid expenses and other current assets


1,052


1,365


Total current assets


20,564


15,684


Investment held for sale


200


200


Property and equipment, net


20,880


19,517


Intangible assets, net


96,652


97,035


Right-of-use assets


18,427


19,094


Deposit


1,050


1,050


Goodwill


1,526


1,526


Other assets


481


425



Total assets



$



159,780



$



154,531



Liabilities


Current liabilities


Accounts payable


7,281


4,808


Accrued liabilities


7,803


7,614


Income taxes payable


10,028


8,925


Derivative liabilities


7,004


7,412


Current portion of notes payable


39,658


38,583


Lease obligations


2,006


1,894


Total current liabilities


73,780


69,236




Notes payable, net of current portion


13,224


13,182


Lease obligations, net of current portion


20,265


20,811


Deferred income taxes


23,465


23,471


Total liabilities



130,734



126,700



Shareholders’ equity


Share capital


141,176


137,835


Share-based compensation reserve


5,704


4,675


Equity conversion feature


11,044


11,044


Warrants


15,200


13,265


Accumulated deficit


(143,705)


(138,609)


Accumulated other comprehensive loss


(374)


(379)


Total shareholders’ equity


29,046


27,831



Total liabilities and shareholders’ equity



$



159,780



$



154,531



CANSORTIUM INC.



STATEMENT OF OPERATIONS



(USD ‘000)



For the three months ended

March 31,



2021



2020


Revenue, net of discounts


$


15,116


$


10,163


Cost of goods sold


5,407


3,660


Gross profit before fair value adjustments


9,709


6,503


Realized fair value of increments on inventory sold


(4,593)


(7,562)


Unrealized change in fair value of biological assets


6,879


12,110


Gross profit


11,995


11,051


Expenses


General and administrative


3,289


3,139


Share-based compensation


3,232


886


Sales and marketing


3,546


3,121


Depreciation and amortization


1,530


1,502


Total expenses


11,597


8,648


Loss from operations


398


2,403


Other expense (income)


Interest expense, net


3,130


3,759


Change in fair market value of derivative liability


(408)


1,835


Equity loss on investment in associate




183


Loss on debt restructuring




8,065


Loss on disposal of assets


48




Other (income) expense


(113)


16


Total other expense (income)


2,657


13,858


Loss before income taxes


(2,259)


(11,455)


Income taxes


2,838


2,833


Net loss


(5,097)


(14,288)


(Gain)/Loss from discontinued operations


(2)


(376)


Net loss after discontinued operations


$


(5,095)


$


(13,912)


Other comprehensive loss:


Foreign exchange translation gain (loss)


5


(70)


Comprehensive loss


$


(5,090)


$


(13,982)


Net loss per share


Basic


$


(0.03)


$


(0.07)


Diluted


$


(0.03)


$


(0.07)



CANSORTIUM INC.



STATEMENT OF CASH FLOWS



(USD ‘000)



For the three months ended

March 31,



2021



2020



Operating activities


Net loss


$


(5,095)


$


(13,912)


Adjustments to reconcile net loss to net cash used in operating activities:


Unrealized gain on changes in fair value of biological assets


(6,879)


(12,110)


Realized gain on changes in fair value of biological assets


4,593


7,562


Share-based compensation


2,151


806


Depreciation and amortization


2,231


1,990


Discontinued operations


(2)


(370)


Accretion of convertible debentures


1,123


1,822


Interest on lease liabilities


618


663


Change in fair market value of derivative


(408)


1,835


Loss on investment in associate




183


Loss on debt restructuring




8,065


Loss on disposal of assets


48




Deferred tax expense


(6)


1,108


Changes in operating assets and liabilities:


Accounts receivable


33


8


Inventory


(1,854)


(1,627)


Biological assets


(1,336)


1,715


Prepaid expenses and other current assets


417


(592)


Other assets


(56)


1


Accounts payable


2,473


998


Accrued liabilities


191


660


Income taxes payable


1,103


1,726


Net cash provided by (used in) operating activities


(655)


531



Investing activities


Purchases of property and equipment


(2,610)


(1,132)


Payment of notes receivable


284




Proceeds from sale of property and equipment


17




Notes receivable


(311)


(339)


Net cash used in investing activities


(2,620)


(1,471)



Financing activities


Proceeds from issuance of shares and warrants


1,891


4,351


Proceeds from issuance of notes payable




62


Payment of lease obligations


(1,052)


(1,064)


Shares issued for interest repayments of notes payable


884




Exercise of warrants


1,275




Principal repayments of notes payable


(6)


(9)


Net cash provided by financing activities


2,992


3,340


Effect of foreign exchange on cash and cash equivalents


5


(70)


Net increase (decrease) in cash and cash equivalents


(278)


2,330


Cash and cash equivalents, beginning of period


3,392


2,516


Cash and cash equivalents, end of period


$


3,114


$


4,846



CANSORTIUM INC.



ADJUSTED EBITDA RECONCILIATION



USD ‘000



Three months ended




March 31,


2021




March 31,


2020



Variance


Net loss


$


(5,095)


$


(13,912)


$


8,817


Interest expense


3,130


3,759


(629)


Income taxes


2,838


2,833


5


Depreciation and amortization


2,232


1,989


243


EBITDA


$


3,105


$


(5,330)


$


8,435



Three months ended



March 31,

2021



March 31,

2020



Variance


EBITDA


$


3,105


$


(5,330)


$


8,435


Change in fair value of biological assets


(2,286)


(4,548)


2,262


Loss on debt restructuring




8,065


(8,065)


Change in fair market value of derivative


(408)


1,835


(2,243)


Share-based compensation


3,232


886


2,346


Discontinued operations


(2)


(376)


374


Loss on disposal of assets


48




48


Other non-recurring expense


697


183


514


Adjusted EBITDA


$


4,386


$


715


$


3,671

Cision
View original content to download multimedia:

http://www.prnewswire.com/news-releases/cansortium-reports-first-quarter-2021-financial-results-301301885.html

SOURCE Cansortium Inc